Private equity sponsors don’t think a cashflow analysis will cure what ails their portfolio companies. They do, however, believe it’s the best first step toward creating a treatment plan that will help right the trajectory of once healthy investments now at-risk. And they’re correct. But, it’s not the same 13-week analysis they’re used to.
